| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2008.12.034 |
| P698 | PubMed publication ID | 19146898 |
| P2093 | author name string | John W Shiver | |
| Xiaoping Liang | |||
| Paul M Keller | |||
| Daniel C Freed | |||
| Tong-Ming Fu | |||
| Joseph G Joyce | |||
| Michael P Citron | |||
| Jiang Fan | |||
| Karen M Grimm | |||
| P2860 | cites work | Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys | Q45604167 |
| Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. | Q45723623 | ||
| Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles | Q45740122 | ||
| Folding and assembly of hepatitis B virus core protein: a new model proposal | Q45762819 | ||
| Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein | Q45771842 | ||
| Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds | Q45852640 | ||
| Improved design and intranasal delivery of an M2e-based human influenza A vaccine | Q49080582 | ||
| Universal influenza A vaccine: optimization of M2-based constructs | Q49115229 | ||
| The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin | Q56906771 | ||
| Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen | Q57213970 | ||
| A simplified method for determination of peptide-protein molar ratios using amino acid analysis | Q67976503 | ||
| Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine | Q74356870 | ||
| Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin | Q80155644 | ||
| Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier | Q81546853 | ||
| Transformation of yeast | Q24605273 | ||
| The crystal structure of the human hepatitis B virus capsid | Q27618957 | ||
| The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging | Q27863808 | ||
| The ion channel activity of the influenza virus M2 protein affects transport through the Golgi apparatus | Q28282474 | ||
| Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling | Q28646159 | ||
| Global epidemiology of influenza: past and present. | Q30326723 | ||
| CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. | Q30367547 | ||
| Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine. | Q33751297 | ||
| A universal influenza A vaccine based on the extracellular domain of the M2 protein | Q33875466 | ||
| Prevention and treatment of influenza | Q34103251 | ||
| A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses | Q34142943 | ||
| HBV core particles as a carrier for B cell/T cell epitopes | Q34339579 | ||
| Vaccine prevention of meningococcal disease, coming soon? | Q34460367 | ||
| Viral ion channels: structure and function. | Q34623321 | ||
| Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate | Q36365841 | ||
| An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. | Q36727331 | ||
| The active oligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer. | Q36764097 | ||
| Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice | Q36802737 | ||
| Role of B cells in antigen presentation of the hepatitis B core | Q36829085 | ||
| Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions | Q36878521 | ||
| A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes | Q37020603 | ||
| Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. | Q37163704 | ||
| Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells | Q39603444 | ||
| Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge | Q40552880 | ||
| Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity | Q40592090 | ||
| N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. | Q40665104 | ||
| Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes | Q41039385 | ||
| Hepatitis B virus capsid: localization of the putative immunodominant loop (residues 78 to 83) on the capsid surface, and implications for the distinction between c and e-antigens. | Q41633348 | ||
| Regulation of pH by the M2 protein of influenza A viruses | Q41636077 | ||
| Antibody response to the M2 protein of influenza A virus expressed in insect cells | Q42070575 | ||
| Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae | Q42686115 | ||
| Unusually high-level expression of a foreign gene (hepatitis B virus core antigen) in Saccharomyces cerevisiae | Q43455558 | ||
| Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface | Q43551346 | ||
| Purification of recombinant HBc antigen expressed in Escherichia coli and Pichia pastoris: comparison of size-exclusion chromatography and ultracentrifugation. | Q44263176 | ||
| Purification of the recombinant hepatitis B virus core antigen (rHBcAg) produced in the yeast Saccharomyces cerevisiae and comparative observation of its particles by transmission electron microscopy (TEM) and atomic force microscopy (AFM). | Q44790019 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | influenza A virus | Q834390 |
| P304 | page(s) | 1440-1447 | |
| P577 | publication date | 2009-01-13 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys | |
| P478 | volume | 27 |
| Q40911284 | 6-(4-Amino-2-butyl-imidazoquinolyl)-norleucine: Toll-like receptor 7 and 8 agonist amino acid for self-adjuvanting peptide vaccine |
| Q28550575 | A Method for Producing Protein Nanoparticles with Applications in Vaccines |
| Q30384304 | A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus |
| Q97881242 | A biomimetic VLP influenza vaccine with interior NP/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy |
| Q30375231 | A broad protection provided by matrix protein 2 (M2) of avian influenza virus. |
| Q41180799 | A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate |
| Q35009732 | A novel M2e based flu vaccine formulation for dogs |
| Q34019854 | AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection |
| Q41918215 | Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses |
| Q58092246 | Chimeric protein consisting of 3M2e and HSP as a universal influenza vaccine candidate: from in silico analysis to preliminary evaluation |
| Q35772241 | Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins |
| Q47159626 | Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice |
| Q40374118 | Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus |
| Q34291098 | Fast vaccine design and development based on correlates of protection (COPs). |
| Q42221819 | Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination |
| Q37645689 | Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus |
| Q30391221 | Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses |
| Q30366089 | Immunogenicity and protective efficacy of recombinant M2e.Hsp70c (Hsp70(359-610)) fusion protein against influenza virus infection in mice. |
| Q38105339 | Immunological assessment of influenza vaccines and immune correlates of protection |
| Q30367793 | Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens. |
| Q30396318 | Influenza A viruses: why focusing on M2e-based universal vaccines |
| Q28743472 | Influenza virus-like particles containing M2 induce broadly cross protective immunity |
| Q47555220 | Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses. |
| Q40571808 | M2-based influenza vaccines: recent advances and clinical potential |
| Q26783493 | M2e-Based Universal Influenza A Vaccines |
| Q35565480 | M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection |
| Q26777740 | Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines |
| Q91327492 | Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population |
| Q37210056 | Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection |
| Q30357932 | New vaccines against influenza virus. |
| Q39780308 | Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens |
| Q33677863 | Newcastle disease virus-like particles: preparation, purification, quantification, and incorporation of foreign glycoproteins |
| Q30407716 | Novel vaccines against influenza viruses. |
| Q34099149 | Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein |
| Q37197051 | Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus |
| Q33582945 | Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein |
| Q34599505 | Recombinant M2e protein-based ELISA: a novel and inexpensive approach for differentiating avian influenza infected chickens from vaccinated ones |
| Q39744811 | Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults |
| Q30403507 | Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q33870745 | Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection |
| Q30373251 | Synthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen. |
| Q54320980 | Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice. |
| Q30430703 | The prospects and challenges of universal vaccines for influenza |
| Q30372479 | The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014. |
| Q27003874 | Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing |
| Q43692141 | Universal influenza vaccine: the holy grail? |
| Q30386388 | Universal influenza vaccines: Shifting to better vaccines. |
| Q45358078 | Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection |
| Q37622906 | Use of hepadnavirus core proteins as vaccine platforms |
| Q41811188 | Vaccination induced antibodies to recombinant avian influenza A virus M2 protein or synthetic M2e peptide do not bind to the M2 protein on the virus or virus infected cells. |
| Q30397930 | Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus |
| Q34105207 | Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice |
| Q59352166 | Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus |
| Q30421558 | Virus-like particles as universal influenza vaccines |
| Q36673724 | Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus |
| Q59205649 | Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine |
Search more.